Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pilar Lim

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Journal of Clinical Psychopharmacology|September 12, 2009
Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysisDavid Hough, Isaac F Nuamah, Pilar Lim, et al.
Journal of Affective Disorders|October 16, 2010
Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled studyJoris Berwaerts, Rosanne Lane, Isaac F Nuamah, et al.
Statistics in Medicine|February 20, 2022
Assessing treatment benefit in the presence of placebo response using the sequential parallel comparison designXiaoyan Liu, Chanmin Kim, Zifei Han, et al.
The International Journal of Neuropsychopharmacology|November 28, 2009
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyMichelle Kramer, Robert Litman, David Hough, et al.
Journal of Clinical Psychopharmacology|January 17, 2007
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled studyMichelle Kramer, George Simpson, Valentinas Maciulis, et al.
Schizophrenia Research|May 1, 2007
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled studyMichael Davidson, Robin Emsley, Michelle Kramer, et al.
Therapeutic Innovation & Regulatory Science|May 27, 2023
Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric DisorderElena Polverejan, Michael O'Kelly, Nanco Hefting, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 1, 2008
Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extensionAndreas Tzimos, Viktor Samokhvalov, Michelle Kramer, et al.
Biological Psychiatry|July 3, 2007
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled studyStephen R Marder, Michelle Kramer, Lisa Ford, et al.
International Clinical Psychopharmacology|October 16, 2008
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studiesRobin Emsley, Joris Berwaerts, Mariëlle Eerdekens, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Journal of Clinical Psychopharmacology|September 12, 2009
Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysisDavid Hough, Isaac F Nuamah, Pilar Lim, et al.
Journal of Affective Disorders|October 16, 2010
Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled studyJoris Berwaerts, Rosanne Lane, Isaac F Nuamah, et al.
Statistics in Medicine|February 20, 2022
Assessing treatment benefit in the presence of placebo response using the sequential parallel comparison designXiaoyan Liu, Chanmin Kim, Zifei Han, et al.
The International Journal of Neuropsychopharmacology|November 28, 2009
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyMichelle Kramer, Robert Litman, David Hough, et al.
Journal of Clinical Psychopharmacology|January 17, 2007
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled studyMichelle Kramer, George Simpson, Valentinas Maciulis, et al.
Schizophrenia Research|May 1, 2007
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled studyMichael Davidson, Robin Emsley, Michelle Kramer, et al.
Therapeutic Innovation & Regulatory Science|May 27, 2023
Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric DisorderElena Polverejan, Michael O'Kelly, Nanco Hefting, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 1, 2008
Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extensionAndreas Tzimos, Viktor Samokhvalov, Michelle Kramer, et al.
Biological Psychiatry|July 3, 2007
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled studyStephen R Marder, Michelle Kramer, Lisa Ford, et al.
International Clinical Psychopharmacology|October 16, 2008
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studiesRobin Emsley, Joris Berwaerts, Mariëlle Eerdekens, et al.
Pageof 5